Sugi Predict

Sugi Predict / Compounds / SCHEMBL3603914

SCHEMBL3603914

SCHEMBL3603914

CC(C)(C)OC(=O)NCCCC[C@@H](N)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.67
▸ GAA P10253 1/20 0.67
▸ KMT2A Q03164 1/20 0.67
▸ TDP1 Q9NUW8 2/20 0.57
▸ MAOA P21397 1/20 0.54
▸ MAOB P27338 1/20 0.54
▸ CA1 P00915 8/20 0.48
▸ CA2 P00918 8/20 0.48
▸ CA12 O43570 6/20 0.48
▸ CA9 Q16790 6/20 0.48
▸ GSR P00390 1/20 0.44
▸ OTC P00480 1/20 0.44
▸ ATM Q13315 1/20 0.42
▸ DPP7 Q9UHL4 1/20 0.41
▸ CHRM2 P08172 2/20 0.41
▸ CHRM4 P08173 2/20 0.41
▸ CHRM5 P08912 2/20 0.41
▸ CHRM1 P11229 2/20 0.41
▸ CHRM3 P20309 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL240701 1.00 MEN1 (0.67) MEN1GAAKMT2ATDP1MAOA
SCHEMBL2311498 1.00 MEN1 (0.67) MEN1GAAKMT2ATDP1MAOA
Hydrochloric Acid SCHEMBL2879159 0.98 MEN1 (0.65) MEN1GAAKMT2ATDP1MAOA
Methane SCHEMBL28937253 0.98 MEN1 (0.65) MEN1GAAKMT2ATDP1MAOA
SCHEMBL30992318 0.98 MEN1 (0.65) MEN1GAAKMT2ATDP1MAOA
Hydrochloric Acid SCHEMBL3201533 0.98 MEN1 (0.65) MEN1GAAKMT2ATDP1MAOA
Hydrochloric Acid SCHEMBL3201523 0.98 MEN1 (0.65) MEN1GAAKMT2ATDP1MAOA
Hydrochloric Acid SCHEMBL23218006 0.97 MEN1 (0.63) MEN1GAAKMT2ATDP1MAOA
Acetic Acid SCHEMBL15812338 0.97 MEN1 (0.63) MEN1GAAKMT2ATDP1MAOA
SCHEMBL20492152 0.96 MEN1 (0.61) MEN1GAAKMT2ATDP1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616732-B2 Peptides for treatment of medical disorders YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) 2026-05-05 — — US disclosed
EP-4727654-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 — — EP disclosed
US-12589101-B2 Cyclodextrin protein drug conjugates REGENERON PHARMACEUTICALS, INC. (US) 2026-03-31 — — US disclosed
US-12503455-B2 Nucleic acid-binding photoprobes and uses thereof ARRAKIS THERAPEUTICS, INC. (US) 2025-12-23 — — US disclosed
US-12497460-B2 Anti-MSR1 antibodies and methods of use thereof REGENERON PHARMACEUTICALS, INC. (US) 2025-12-16 — — US disclosed
US-20250296959-A1 B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC (US) 2025-09-25 — — US disclosed
CN-119930814-A D-peptide compounds directed against VEGF 反射制药有限公司 2025-05-06 — — CN disclosed
CN-119060121-B Synthesis method of oligopeptide-1 山东美欣生物科技有限公司 2025-03-14 — — CN disclosed
US-20250064954-A1 STEROIDS AND ANTIBODY-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. 2025-02-27 — — US disclosed
US-20250049970-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC (US) 2025-02-13 — — US disclosed
US-20100168075-A1 Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions ASTRAZENECA AB (SE) 2010-07-01 — — US disclosed
US-20090264300-A1 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES NUEVOLUTION A/S (DK) 2009-10-22 — — US disclosed
US-20090264300-A1 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES NUEVOLUTION A/S (DK) 2009-10-22 — — US disclosed
EP-2013165-A1 DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSOR TION INHIBITOR ACTIVIT. Astra Zeneca AB (SE) 2009-01-14 — — EP disclosed
WO-2009002529-A2 LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), BIOLOGICAL EVALUATION, AND USE AS IMAGING AGENTS THE JOHNS HOPKINS UNIVERSITY (US) 2008-12-31 — — WO disclosed
WO-2007126358-A1 DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSOR TION INHIBITOR ACTIVIT. ASTRAZENECA AB (SE) 2007-11-08 — — WO disclosed
WO-2007062664-A2 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES NUEVOLUTION A/S (DK) 2007-06-07 — — WO disclosed
US-6887890-B2 Compounds exhibiting thrombopoietin-like activities CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-05-03 — — US disclosed
US-20030162724-A1 Compounds exhibiting thrombopoietin-like activities CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-08-28 — — US disclosed
EP-1291341-A1 COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-03-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264300-A1 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES RNGTT, DUT, EMG1 MEN1 3861/4885GAA 176/4885KMT2A 1082/4885
US-12589101-B2 Cyclodextrin protein drug conjugates SSB, CHP1, IAPP MEN1 4095/4885GAA 389/4885KMT2A 4692/4885
US-20250296959-A1 B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF CD274, CD44, CD74 MEN1 640/4885GAA 2418/4885KMT2A 322/4885
US-20250064954-A1 STEROIDS AND ANTIBODY-CONJUGATES THEREOF SERPINA6, NR3C1, NR3C2 MEN1 2331/4885GAA 2471/4885KMT2A 4385/4885
US-12503455-B2 Nucleic acid-binding photoprobes and uses thereof NSUN3, NSUN2, TARBP1 MEN1 4474/4885GAA 1966/4885KMT2A 2159/4885
US-20030162724-A1 Compounds exhibiting thrombopoietin-like activities MPL, THPO, TEK MEN1 111/4885GAA 4704/4885KMT2A 2704/4885
US-20250049970-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF DLK1, DBNL, PDLIM5 MEN1 528/4885GAA 2163/4885KMT2A 2586/4885
US-12497460-B2 Anti-MSR1 antibodies and methods of use thereof CD47, MSR1, LDLR MEN1 1417/4885GAA 2281/4885KMT2A 710/4885
US-12616732-B2 Peptides for treatment of medical disorders OPRK1, OPRD1, OPRL1 MEN1 4190/4885GAA 3685/4885KMT2A 3236/4885
US-20100168075-A1 Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions CYP46A1, NPC1L1, NPC1 MEN1 726/4885GAA 227/4885KMT2A 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.